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 This scoping review reveals a growing literature on the effects of certain state opioid misuse 
prevention policies, but persistent gaps in evidence on other prevalent state policies remain.  
 Policymakers interested in reducing the volume and dosage of opioids prescribed and 
dispensed can consider adopting robust prescription drug monitoring programs with 
mandatory access provisions and drug supply management policies, such as prior 
authorization policies for high-risk prescription opioids. 
 Further research should concentrate on potential unintended consequences of opioid misuse 
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received sufficient evaluation (eg, Good Samaritan laws, naloxone access laws), and patient-
related outcomes.  
Context: In the midst of an opioid crisis in the United States, an influx of state opioid misuse 
prevention policies has provided new opportunities to generate evidence of policy effectiveness that 
can inform policy decisions. We conducted a scoping review to synthesize the available evidence on 
the effectiveness of US state interventions to improve patient and provider outcomes related to opioid 
misuse and addiction.  
Methods: We searched six online databases to identify evaluations of state opioid policies. Eligible 
studies examined legislative and administrative policy interventions that evaluated (a) prescribing and 
dispensing, (b) patient behavior, or (c) patient health. 
 
Findings: Seventy-one articles met our inclusion criteria, including 41 studies published between 
2016 and 2018. These articles evaluated nine types of state policies targeting opioid misuse. While 
prescription drug monitoring programs (PDMPs) have received considerable attention in the 
literature, far fewer studies addressed other types of state policy. Overall, evidence quality is very low 
for the majority of policies due to a small number of evaluations. Of interventions that have been the 
subject of considerable research, promising means of reducing the volume and dosages of opioids 
prescribed and dispensed include drug supply management policies and robust PDMPs. Due to low 
study number and quality, evidence is insufficient to draw conclusions regarding interventions 
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Conclusions: Recent research has improved the evidence base on several state interventions targeting 
opioid misuse. Specifically, moderate evidence suggests that drug supply management policies and 
robust PDMPs reduce opioid prescribing. Despite the increase in rigorous evaluations, evidence 
remains limited for the majority of policies, particularly those targeting patient health–related 
outcomes. 
 
Keywords: opioid, state policy, scoping review, drug overdose. 
The United States is in the midst of an opioid overdose crisis. In 2017 there were 70,237 drug 
overdose deaths in the United States, 47,600 of which were attributable to opioids.
1,2
 Prescription 
opioid medications caused most fatal opioid overdose deaths in the first decade of the 2000s.
3
 
Although today most opioid overdoses involve heroin and illicit fentanyl, many who experience 
opioid harms were first exposed to opioids via a prescription.
1,4
  
States have implemented a panoply of preventive measures in recent years to address health 
consequences associated with opioid misuse and addiction. These state policies target prevention at 
different levels, from primary prevention of initial exposure to opioids, to secondary prevention to 
avoid high-risk opioid exposure, to tertiary prevention to treat individuals with opioid use disorder.
5,6
 
Table 1 summarizes this array of approaches. While these prevention categories are not mutually 
exclusive, we place each state policy within a prevention group to facilitate organization of policies 
based on their chief intent.  
Previous studies aggregated evidence from specific interventions
7,8
 and integrated strategies 
in a single review.
9,10
 Reviews published in the past two years of prescription drug monitoring 
program (PDMP) evaluations are inconclusive with regard to PDMP effects on overdose and other 
outcomes.
7,8
 Reviews that synthesize evaluations of multiple interventions published prior to 2016 
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targeting insurance practices, pain clinic regulations, clinical guidelines, and naloxone access laws.
9,10
 
However, they also highlighted that evidence quality was low and that rigorous evaluations were 
needed to further investigate policy effects.
9,10
 Since the publication of these reviews, state policies 
have evolved significantly and original empirical evaluations of state interventions have improved in 
study rigor,
6
 suggesting that an updated review would provide additional insight into the effects of 
state policies targeting opioid misuse and overdose.  
This scoping review aims to synthesize the available evidence on the effectiveness of 
prevalent state opioid policies on improving outcomes related to opioid prescribing and dispensing, 
patient behavior, and patient health. Given the recent increase in the adoption of state opioid policies 
and interest among policymakers to address the opioid crisis, we hypothesized that the evidence base 
evaluating these policies would have grown substantially in recent years, offering a clearer sense of 
policy effects on patient and prescriber outcomes. We also hypothesized that policies would 
demonstrate more significant effects on the outcomes most closely related to the behavior(s) they 
target. Specifically, we expected primary and secondary prevention policies to be most associated 
with changes in outcomes related to opioid prescribing and dispensing and patient behavior, and 
tertiary prevention strategies to have the greatest impacts on patient health. Finally, we expected that 
promising policies identified by previous reviews—specifically PDMPs, policies targeting insurance 
practices, pain clinic regulations, clinical guidelines, and naloxone access laws—would have the 
largest effects on provider- and patient-related outcomes compared to other state laws.  
 
Methods 
 We systematically identified and synthesized findings from empirical evaluations of state 
opioid misuse prevention programs. 








Following consultation with an informationist at the Taubman Health Sciences Library at the 
University of Michigan, we searched six online literature databases: Cumulative Index to Nursing and 
Allied Health Literature Complete, Criminal Justice Abstracts, the National Bureau of Economic 
Research (NBER), PubMed, PsychINFO, and Scopus. We conducted the initial search in PubMed; 
searches in other databases, with the exception of NBER, were analogous to the original search. In 
NBER, we searched ―opioid‖ and reviewed all yielded articles for inclusion. We examined references 
from the selected materials to identify additional articles that met the inclusion criteria. To ensure that 
we captured all relevant studies, we compared our yielded articles with the evaluations included in the 
following review papers: Haegerich et al., 2014;
9
 Beaudoin et al., 2016;
10
 Finley et al., 2017;
8
 and 
Fink et al., 2018.
7
 We conducted the search in summer 2018 and no additional articles were added 
after September 1, 2018. All of the resulting citations and abstracts were exported to Mendeley 1.19.1. 
We did not impose a date restriction on searches. See Appendix 1 for terms and the algorithm used in 




 Inclusion in the scoping review required that the original quantitative research article be 
written in English and evaluate the effect of a US state policy on a patient- or provider-related 
outcome (defined below). We defined state policy as a legislative or administrative action, such as a 
law or regulation, that directly targeted opioid misuse. For example, naloxone access laws are a 
legislative action in that they intend to affect naloxone access by modifying statutorily who is allowed 
to prescribe, dispense, and possess naloxone. We also included PDMPs because they are most often 
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that were not triggered by law passage or rulemaking, with the exception of drug supply management 
policies and opioid prescribing guidelines. While state funded and administered programs play a large 
part of public strategies to address opioid misuse and overdose, we focused on state initiatives with a 
policymaking component to inform activities directly relevant to legislative and regulatory 
policymakers. As a result, we determined that evaluations of state programs not triggered by a law or 
regulation were generally beyond the scope of this review; other studies have synthesized the 
evidence on the effects of these programs.
9,11,12
 
 We included drug supply management policies (eg, quantity and dosing limits, prior 
authorization restrictions) and opioid prescribing guidelines, both of which can be implemented 
through informal policymaking, such as bulletins, guidelines, and Medicaid protocols, for three  
reasons. First, these policies are an important state policy tool in promoting or restricting access to 
opioids and medications used in the treatment of opioid dependence. Second, state actors, depending 
on the state, can use their formal policymaking powers to enact these policies and guidelines. Third, it 
is unclear from the articles included in this section whether state actors enacted the policy through a 
formal or informal policymaking process.  
We required that the original empirical research study assess at least one of the following 
outcomes: prescribing/dispensing (eg, volume of opioids prescribed or dispensed, opioid dosage 
prescribed or dispensed), patient behavior (eg, use of multiple providers or pharmacies, diverted 
opioids), and patient health (eg, fatal and nonfatal overdose, treatment visits). Outcomes classified as 
opioids prescribed or dispensed include total/monthly/daily opioid prescriptions, dispensed controlled 
substances, mean per person per month fills, and days supplied. Outcomes classified as opioid dosage 
prescribed include average and per-transaction morphine milligram equivalent (MME) dosage; and 
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We excluded qualitative studies, book chapters, review articles, dissertations, editorials, 
letters to the editor, and purely descriptive studies. We did not place restrictions on sample size or 
age. Eligible studies were peer-reviewed or published in Morbidity and Mortality Weekly Report or 
NBER. Two authors independently reviewed articles for inclusion, while a third author resolved 
outstanding conflicts regarding study inclusion. 
 
Policies Evaluated  
 
 Included articles reviewed nine types of state policy: three primary prevention strategies (ie, 
continuing medical education requirements, laws related to pain management clinics, and opioid 
prescribing guidelines); three secondary prevention strategies (ie, anti-doctor-shopping laws, drug 
supply management policies, and PDMPs); and three tertiary prevention strategies (ie, naloxone 
access laws, Good Samaritan laws, and policies affecting opioid addiction treatment).  
 
 
Continuing Medical Education Requirements. State continuing medical education 
requirements for pain management or controlled substances mandate that physicians receive 
postgraduate training in opioid prescribing, addiction, and/or related topics. As of December 2015, 23 
states required at least some physicians to receive training in pain management or controlled-
substance prescribing as a condition of obtaining or renewing their medical license or to specialize in 
pain management. Only five states required all or nearly all physicians to obtain periodic continuing 











Laws Related to Pain Management Clinics. Pain management clinic policies regulate 
facilities that primarily manage and treat chronic pain by imposing operational, personnel, inspection, 





Opioid Prescribing Guidelines. Opioid prescribing guidelines provide recommendations to 
providers on opioid prescribing practices. Guidelines vary but typically include opioid selection, 
dosage, duration, titration, and discontinuation; screening tools; written treatment agreements; and 
urine drug testing. As of July 2017, 41 states had adopted opioid prescribing guidelines for acute or 
emergency care.
16
 This domain may include both payor policies embedded in informal regulatory 
actions (eg, Medicaid prescribing guidelines) and state laws or regulations requiring the development 
and implementation of prescribing standards. See the section on eligibility criteria inclusion 
parameters regarding opioid prescribing guidelines. 
 
Anti-Doctor-Shopping Laws. Doctor shopping refers to a patient obtaining controlled 
substances from multiple health care prescribers without the providers‘ knowledge of the other 
prescriptions. All 50 states and the District of Columbia have a general fraud statute, which prohibits 
patients from obtaining drugs by fraud, deceit, misrepresentation, subterfuge, or concealment of 
material fact. As of 2012, 20 states also have laws that specifically prohibit patients from withholding 
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Drug Supply Management Policies. Drug supply management policies limit opioid 
prescribing by restricting quantity or dosage that can be prescribed, or by imposing prior authorization 
requirements or fail-first protocols (whereby insurers require a treatment to be demonstrated as 
ineffective before they will approve a more expensive treatment). Such restrictions can apply to public 
programs and/or private plans regulated at the state level. This domain may include both payor 
policies embedded in informal regulatory actions (eg, Medicaid plan protocols) and state restrictions 
affecting private and/or public payors enacted through statute or regulation (eg, statutory prohibition 
of all state-regulated payors from applying concurrent review to daily buprenorphine formulations). 
See the section on eligibility criteria inclusion parameters regarding drug supply management policies 
in the analysis. 
 
PDMPs. A PDMP is an electronic database that tracks controlled-substance prescriptions 
dispensed in a state. PDMPs can be used as a clinical tool to help identify patients who may be at risk 
for adverse consequences associated with high-risk prescription opioid receipt. Since the 1990s, 
PDMPs have proliferated across the country; now all states except Missouri have an operational 
program.
18
 PDMPs vary in their features, with the most robust PDMPs requiring prescribers to 
register and query the database before prescribing opioids. 
 
 
Naloxone Access Laws. Naloxone is an opioid antagonist designed to rapidly reverse opioid 
overdose. Naloxone access laws are designed to increase access to naloxone among those in a position 
to administer the medication in the event of overdose. Laws vary but can include the following 
provisions: (1) third-party prescriptions, which permit naloxone to be prescribed to third parties who 
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individuals without a prescription, such as standing order, collaborative practice agreements, and full 
prescriptive authority; (3) prescriber immunity provisions, which provide civil or criminal immunity 
to naloxone prescribers; and (4) lay dispensing provisions, which allow persons not otherwise 
permitted to dispense prescription medications to dispense naloxone. As of December 2018, all states 
and Washington, DC, had a naloxone access law: 48 had a third-party prescribing provision and 44 




Good Samaritan Laws. Good Samaritan laws provide legal protection for persons who 
overdose and bystanders who call emergency authorities during an overdose event. These laws vary in 
specific criminal protections for drug possession, drug paraphernalia, and parole or probation 





Policies Affecting Opioid Addiction Treatment. This category includes policies that 
influence access to treatments for opioid addiction, such as residential treatment and medication-
assisted treatment. Policies vary greatly but include mandating or restricting benefit coverage for 
opioid use disorder, modifying public funding for treatment, or imposing provider licensing 
requirements. Articles included in this review assess policies related to buprenorphine access, 
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We extracted data using a standardized article assessment form that captured the following 
elements: policy studied, outcome data source, study design, study years, sample, results, and 
limitations (Appendix 2). The limitations extracted focus on information relevant to sampling and 
covariate inclusion. Two authors independently reviewed ten randomly selected articles and entered 
relevant content into the extraction table. The same two authors reviewed the ten extractions for 
consistency and to resolve differences. One author then completed article extraction for the other 61 




Due to heterogeneity in the policies and outcomes evaluated, we performed a qualitative 
assessment and synthesis. We categorized policies as (1) primary prevention; (2) secondary 
prevention; and (3) tertiary prevention. Table 1 summarizes these policies but is not an exhaustive list 
of state strategies to address opioid misuse, overdose, and prescribing; it lists only the state policies 
assessed in the original empirical articles included in this review.  
We categorized articles using the following three-step procedure. First, we organized studies 
by research design using a simplified hierarchy adopted from Haffajee (2016) (see Appendix 3).
22
 
Although not exhaustive of the different types of study designs used to assess public health legal 
interventions, the hierarchy aids policymakers in evaluating evidence quality to make policy 
decisions. Next, we classified studies into three categories based on outcomes evaluated: prescribing 
and dispensing, patient behavior, and patient health. We included studies that evaluated multiple 
outcomes in all relevant outcome categories. Finally, we organized studies by policy type evaluated. 
Similar to outcome categories, we classified studies that evaluated the independent effects of multiple 
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We rated the quality of evidence for each policy/outcome group using a modified Grading of 
Recommendations, Assessment, Development and Evaluations (GRADE) approach.
23,24
 The GRADE 
framework is a systematic strategy for rating the quality of a body of evidence for synthesis with the 
following quality grades: high quality—further research is very unlikely to change our confidence in 
the estimate of the effect; moderate quality—further research is likely to have an important impact on 
our confidence in the estimate of the effect and may change the estimate; low quality—further 
research is very likely to have an important impact on our confidence in the estimate of the effect and 
is likely to change the estimate; very low quality—we are very uncertain about the estimate of the 
effect. 
Our modified GRADE approach employs the following procedure. First, we assigned all 
policy and outcome groups a low quality of evidence score, as the GRADE approach rates all 
observational studies a low score and all of our included articles used an observational design. 
Second, we modified the original GRADE score based on factors that can reduce or increase the 
quality of evidence. Factors that can reduce the quality of evidence include limitations in study design 
or execution, result inconsistency, indirectness of evidence, imprecision, and publication bias. Factors 
that can improve the quality of evidence include effect size and if unaccounted-for confounding is 
suspected to strengthen the findings. We automatically assigned a very low quality of evidence score 
for policy/outcome groups with only one evaluation. We did not assign a GRADE score to outcomes 
associated with multiple policies because articles within this category evaluate different combinations 
of policies. Since the GRADE approach rates the quality of evidence across evaluations of the same or 
very similar interventions, we do not believe that it is appropriate to assign a GRADE score to the 
synthesized findings of articles evaluating different combined interventions. The GRADE scores 










Figure 1 depicts the literature search and selection process; 71 articles met the inclusion 
criteria. Table 2 provides a summary of the articles included in the review: 10 assessed primary 
prevention interventions, 44 assessed secondary prevention interventions, and 12 assessed tertiary 
prevention policies. Studies most frequently evaluated PDMPs (n = 38), followed by opioid addiction 
treatment policies (n = 7) and laws related to pain management clinics (n = 4). The number of articles 
by publication year ranged from 41 in 2016-2018 to 2 between 1980 and 2000 (see Appendix 5 for a 
visual depiction of number of articles published annually by policy type).  
The following sections provide an overall summary of the evidence evaluating each policy. 
As is detailed later in the paper, contradictory rigorous evaluations on laws related to pain 
management clinics provide mixed findings on the effects of these policies on prescribing outcomes. 
Evidence suggests that drug supply management laws and robust PDMPs reduce opioid prescribing 
and dispensing. Specifically, drug supply management policies reduce prescribing of higher-risk 
opioids targeted by the policies, while increasing the frequency of lower-risk prescriptions. Robust 
PDMPs with mandatory access provisions were associated with reductions in a variety of opioid 
prescribing measures, including total prescriptions and number of opioid fills. Across interventions, 
the quality of evidence on patient health outcomes is insufficient to facilitate conclusions. Of the 19 
policy and outcome groups, 13 (68.4%) received a very low quality of evidence score; 5 (26.3%) 
received a low score; and 1 (5.3%) received a moderate score.  
In the subsequent policy results sections, we focus on the most rigorously designed studies, 
which are more appropriate for causal inference. Studies of weaker design for causal inference are 
described in Tables 3 to 6 and Appendices 3 and 5. All findings reported are significant at the 0.05 
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at the 0.05 level. See Appendix 2 for more detailed quantitative results, including effect estimates and 
confidence intervals. 
 
Continuing Medical Education Requirements 
 
 Evidence on statutory or regulatory continuing medical education requirements is extremely 
limited due to the single evaluation that met our inclusion criteria and thus received a very low quality 
of evidence score. The one study in this category assessed prescribing behaviors among clinicians 
before and after a 2012 New Mexico Senate law, which required all health care professional licensing 
boards to mandate continuing medical education training for the treatment of chronic pain. The 
authors observed a reduction in high opioid prescription dosages (>100 MME per day) and an 
increase in moderate opioid prescription dosages (≤40 MME per day). They observed slight increases 




Laws Related to Pain Management Clinics 
 
 Based on available evidence, it is unclear whether laws related to pain management clinics 
exert a direct, combined, or null effect on opioid prescribing. Only one evaluation, by Lyapustina and 
colleagues (2016) of the 2010 Texas pain management clinic law, observed reductions in opioids 
prescribed, including average MME per transaction, total opioid volume (ie, total MME across all 
transactions), number of opioid prescriptions, and quantity of opioid pills dispensed, following policy 
implementation.
31
 However, other studies suggest that laws related to pain management clinics have 
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association between pain management clinic laws and MMEs prescribed per state resident.
28
 Evidence 
from Meara and colleagues (2016) further suggests that laws related to pain management clinics do 
not affect opioid prescribing. Using a sample of Medicare beneficiaries, the authors observed no 
association between pain clinic regulations and non-long-term opioid receipt and opioid dosage 
greater than 120 daily MME.
27
 Further, other rigorous evaluations suggest that the potential effects of 
pain management clinic laws on opioid prescribing may occur only in combination with other 
policies. The evaluation conducted by Dowell and colleagues, while not identifying an independent 
effect of these policies, observed that states with both pain management clinic laws and mandatory 
provider review of the state PDMP experienced decreases in opioid MME prescribing rate.
28
 In 
addition, several evaluations of the 2010-2011 Florida policies targeting opioid misuse observed 
PDMPs and pain management clinic policies together were associated with reductions in opioids 
prescribed. Florida introduced these policies in quick succession (see section on combined effects of 
multiple policy interventions).
53,86-88
 Given that the initial Florida PDMP implemented on September 
1, 2011, was relatively weak, since it did not contain critical provisions, such as registration or use 
mandates, it is challenging to attribute the entirety of the change in opioid prescribing to the PDMP, 




 Two rigorous evaluations suggest that pain clinic laws alone have no effect on patient health 
outcomes. Dowell and colleagues did not identify an association between pain clinic laws and 
prescription opioid overdose deaths, heroin overdose deaths, and combined drug overdose deaths.
28
 
However, states with both pain clinic laws and mandatory provider review experienced decreases in 
prescription opioid overdose deaths and combined drug overdose deaths, but not heroin overdose 
deaths.
28
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Opioid Prescribing Guidelines 
 
 We identified only one rigorous evaluation that observed significant reductions in opioid 
prescribing behaviors following state opioid guideline implementation. Weiner and colleagues (2017) 
evaluated the Ohio 2012 emergency physician guidelines that encouraged physicians to check the 
Ohio PDMP before prescribing controlled medication and urged physicians to limit the quantity of 
opioids prescribed to no more than a three days‘ supply, among other provisions. The guideline was 
associated with a 12% decrease in the level of statewide total monthly opioid prescriptions. No 






Evidence on anti-doctor-shopping laws is extremely limited and of very low quality. Only 
two studies met the inclusion criteria for this category, both of which assessed the independent effects 
of multiple state opioid prevention policies, including doctor-shopping restrictions.
26,27
 Neither study 
identified an association between anti-doctor-shopping laws and opioid prescribing outcomes. 
 
Drug Supply Management Policies 
 
Existing evidence suggests that prior authorization laws fulfill their intended effect of limiting 
access to higher-risk opioids targeted by the policies. Hartung and colleagues (2018) evaluated a 2012 
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prescriptions; the study demonstrated a decrease in opioid prescriptions above the high-dosage 
threshold and an increase in the monthly probability of low-dosage opioid prescriptions following 
policy implementation.
37
 Keast and colleagues (2018) found that a 2008 Oklahoma Medicaid prior 
authorization policy that required a trial of short-acting opioids prior to initiating extended 
release/long-acting therapy resulted in a reduction in new extended release/long-acting opioid use 
among opioid-naïve patients and regardless of past opioid use. The policy also was associated with an 
increase in short-acting opioid use.
38
 
Research by Morden and colleagues (2018) suggests that prior authorization policies of 
varying stringency have differential effects on controlled-release oxycodone use.
39
 The authors 
compared strict, lenient, and no prior authorization policies using outpatient fee-for-service Medicaid 
prescription claims in 49 states and the District of Columbia. States with prior authorization policies 
did not differ in controlled-release oxycodone use from states without prior authorization policies. 
However, in aggregate, strict Medicaid prior authorization policies were associated with a 34% 
reduction in controlled-release oxycodone use.39  
Prior authorization policies may be effective at reducing outcomes related to doctor shopping. 
Two rigorous evaluations observed that prior authorization policies were associated with decreases in 
multiple pharmacy or prescriber use. Hartung and colleagues observed a small decrease in multiple 
pharmacy visits following policy implementation.
37
 Among persons with high-risk opioid use, Keast 




The evidence on the effect of drug supply management policies on patient health outcomes is 
extremely limited and of very low quality. The one rigorous evaluation available suggests that a prior 
authorization policy for high-dosage prescriptions (>120 MME) had no effect on opioid-related 
emergency department visits or hospitalizations.
37
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Prescription Drug Monitoring Programs 
 
Although studies evaluating PDMPs have mixed results across outcomes, certain PDMP 
features (specifically, mandatory access provisions) show more promise in reducing opioids 
prescribed. 
 
PDMPs Overall. Evidence from the most rigorous evaluations suggest that PDMPs have no 
effect on opioid prescribing overall but may reduce higher-risk prescribing behaviors. For example, 
Moyo and colleagues (2017) observed that PDMP implementation is associated with decreases in 
schedule II and schedule III opioid prescriptions, but has no effect on mean overall MME, total 
schedule IV, or schedule V opioids dispensed.
42
 Research by Bao and colleagues (2016) using the 
National Ambulatory Medical Care Survey suggests that PDMPs reduce schedule II prescriptions, but 
do not affect total opioid and pain medication prescriptions.
43
 Other rigorous evaluations suggest that 
PDMPs have no effect on opioid dosage prescribed. Of the 4 evaluations that measured opioid dosage 
before and after PDMP implementation compared to a control group, no study identified a change in 
opioid dosage following policy implementation.
42,44-46
 
The published evidence on the effects of PDMPs on patient health outcomes is also heavily 
mixed. Thirteen studies evaluated the independent effects of PDMPs on patient health. Outcomes 
varied greatly by study and included overdose mortality; drug use, misuse, dependence, and initiation; 
and health care use. Studies considered both illicit (eg, heroin and nonmedical prescription pain 
reliever use) and legal prescription drug use. Due to the variation in the outcomes considered, and the 
mixed results across studies that evaluated similar outcomes, more research is needed to clarify the 
effect of PDMPs on patient-health-related measures. One rigorous evaluation provides evidence on 
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noninstitutionalized individuals 12 years or older, Ali and colleagues (2017) observed that PDMPs 




PDMP Features. Recent studies on the adoption of robust PDMP features suggest that 
PDMP design influences effectiveness, helping to clarify the mixed results on PDMPs overall. Robust 
PDMPs with mandatory access provisions are associated with decreases in opioid prescribing and 
reduced doctor-shopping-related behaviors, compared to PDMPs without these provisions.  
Studies most commonly evaluated mandatory access provisions, which require practitioners 
to check a PDMP before prescribing or dispensing an opioid. Findings from these evaluations suggest 
that mandatory access provisions are associated with reductions in opioid prescribing behaviors. For 
example, Suffoletto and colleagues‘ (2018) evaluation of a 2016 Pennsylvania mandatory access 
provision identified a reduction in the opioid prescribing rate using electronic medical record data 
from 15 emergency departments in a single health system.
71
 Buchmueller and colleagues (2018) found 
that mandatory access provisions were associated with a decline in the probability of receiving 
opioids.
45
 Wen and colleagues (2017) found that the effect of mandatory access provisions may 
actually be explained by the presence of a mandatory registration provision in the Medicaid 
population, suggesting that further research should explore interactions among features.
74
  
Mandatory access provisions also appear to be associated with reductions in behaviors related to 
doctor shopping. Two rigorous studies, by Ali and colleagues (2017) and Buchmueller and colleagues 





 multiple pharmacy visits,
45
 and overlapping claims,
45
 but had no 
effect on social or illegitimate opioid source use.
45
 Similar to overall PDMPs, results are mixed on the 
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Robust PDMPs, defined as those with multiple provisions (notably, use and registration 
mandates and delegate access) known or hypothesized to improve the ability of prescribers to use and 
access PDMPs, also appear to reduce opioid prescriptions. Haffajee and colleagues (2018) used 
commercial claims data between 2010 and 2014 to examine the effects of four robust PDMPs on 
overall and high-risk opioid prescribing compared to results in four similar states without robust 
PDMPs. The authors observed that robust PDMP implementation was associated with declines in total 
opioid dosage prescribed and number of opioid fills. Robust PDMPs were less consistently associated 
with reduced percentage of patients prescribed opioids, with the magnitude and significance of the 
effects varying by state. The authors also assessed the effect of robust PDMPs on opioid prescriptions 
filled by three or more prescribers and pharmacists, observing a decrease only in Kentucky, compared 




Good Samaritan Laws 
 
Few studies have evaluated Good Samaritan laws and thus, while robust in design, the quality 
of evidence assessing the effect of these laws on patient health is low. One rigorous evaluation by 
Nguyen and colleagues (2018) suggests that, consistent with its goals, the 2011 New York Good 
Samaritan law was associated with increased heroin-related acute hospital utilization. However, the 
policy had no effect on nonheroin opioid-related visits, supporting the authors‘ hypothesis that the law 
would have a greater effect on heroin-related overdose than non-heroin-related events because the 
threat of charge and conviction is less salient for non-heroin cases.
76
 Conversely, Rees and colleagues‘ 
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Policies Affecting Opioid Addiction Treatment 
 
Due to variation in the policies evaluated and outcomes considered, we are unable to draw 
conclusions about the effects of policies influencing opioid addiction treatment. Further, no study 
included in this category longitudinally evaluated changes in a treatment group compared to a control 
group, limiting our ability to infer causal policy effects. Of the seven less rigorous studies that met the 
inclusion criteria in this category, four articles assessed policies related to methadone and suggest that 
Medicaid coverage restrictions for methadone may be associated with decreased treatment 
use.
78,79,81,83,
 One rigorous article evaluated policy changes related to buprenorphine access. Clark and 
colleagues (2014) observed that a 2008 Massachusetts Medicaid policy requiring more frequent prior 
authorization for higher-dose buprenorphine prescriptions was associated with a decrease in the 





Naloxone Access Laws 
 
 Few studies have evaluated the effects of state naloxone access laws. Evidence from two 
rigorous evaluations, Gertner et al. (2018) and Xu et al. (2018), suggests that naloxone access laws 
increase prescription naloxone dispensing overall.
84,85
 Xu et al. found that naloxone access laws are 
associated with a 79% increase in naloxone prescriptions dispensed per state-quarter. Xu et al. also 
found an independent effect of both standing-order provisions and third-party prescribing provisions 
on naloxone prescribing.
85
 But Gertner et al. found that the presence of a standing-order provision was 
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provision corresponded to an increase of 33.1 dispensed prescriptions per state-quarter, or 74% of the 
average number of naloxone prescriptions dispensed.
84
  
Evidence from the rigorous study by Rees et al. suggests that naloxone access laws reduced 
overall opioid-related mortality by 9%. This effect was significant for non-heroin opioid-related 
mortality but not heroin-related mortality. In addition, the overall effect was limited to naloxone 
access laws that remove criminal liability for naloxone possession.
29  
 
Combined Effects of Multiple Policy Interventions 
 
Ten articles evaluated the combined effect of multiple policies,
28,53,86-93
 including seven 
interested in the 2010-2011 Florida law enforcement, pharmaceutical, and public health 
interventions.
53,86-88,91-93
 Florida state activities during this period included a January 2010 requirement 
that pain management clinics register with the Florida Department of Health, a July 2011 law that 
strengthened state regulation of activities by controlled-substance dispensing entities, and the 
implementation of the Florida PDMP in October 2011. Overall, the evidence suggests that combined 
policies corresponded to reductions in opioid prescribing, lower diversion rates for some types of 
opioid, and potentially fewer prescription opioid overdose fatalities. 
Three rigorous evaluations suggest that the combined 2010-2011 Florida interventions were 
associated with reductions in opioids prescribed, with effects concentrated among the highest baseline 
opioid users and prescribers.
86-88
 Surratt and colleagues (2014) observed a decline in diversion rates 
following implementation of the Florida policy interventions. Using data from the Researched Abuse 
Diversion and Addiction-Related Surveillance System from 2009 to 2012, the authors identified a 
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change in diversion rates for fentanyl, hydrocodone, hydromorphone, or buprenorphine.
91
 One 
rigorous evaluation found that these policies were associated with reductions in mortality related to 
prescription opioids. Kennedy-Hendricks and colleagues (2016) compared drug overdose deaths from 
2003 to 2012, observing a reduction in prescription opioid overdose mortality of 0.6 per 100,000 in 
2010, 1.8 per 100,000 in 2011, and 3.0 per 100,000 in 2012 in Florida compared to North Carolina.
92 




Two articles evaluated other state policies containing multiple opioid-relevant components; 
results were generally consistent with evaluations of the Florida laws. Sun and colleagues (2017) 
investigated a 2012 Washington state mandate that required hospitals to implement seven best 
practices to reduce potentially avoidable emergency department visits by Medicaid beneficiaries, 
including several mandates that directly or indirectly targeted opioid prescribing.
90
 The authors 
observed that the mandates were associated with a small reduction in number of opioid prescriptions 
dispensed in the overall, prior risky opioid use, and chronic opioid use cohorts. However, there was 
no overall or subgroup change in MME per dispensed prescription.
90
 Al Achkar and colleagues (2018) 
measured the change in total opioids dispensed in Indiana before and after a 2013 opioid prescribing 
emergency rule that required providers to, for certain patients, (1) evaluate opioid recipients for 
psychiatric conditions; (2) review patients‘ drug prescription history in Indiana‘s Prescription 
Electronic Collection and Tracking Program ; (3) perform regular drug screenings; and (4) obtain a 
signed controlled-substance agreement from the patient.
89
 The emergency rules were associated with 
an instantaneous decrease in daily MMEs per patient for all opioids, hydrocodone, oxycodone, 













States can wield a variety of legal tools to address opioid misuse; these tools warrant 
evaluation to identify the best use of resources in tackling the opioid crisis. Recent research articles 
add rigor to the body of evidence assessing opioid misuse policies. In contrast with earlier reviews 
that identified few rigorous empirical evaluations in this area, more than half of our included studies 
used quasi-experimental designs helpful for causal inference (eg, interrupted time series or pre-post 
test designs compared to a control group).
9
 Despite recent improvements in methodological rigor 
overall, the lack of consistent rigor within policy type and outcome groups limits our ability to 
confirm our second hypothesis, that policies would have the most significant effect on the outcome 
most closely related to their intent. Only 6 of our policy and outcome groups did not receive a very 
low GRADE rating, challenging our ability to synthesize the evidence within policy and outcome 
groups.  
Despite insufficient evaluation of many policies, research has identified several state opioid 
misuse prevention policies that appear to influence opioid prescribing and dispensing. Evidence on 
drug supply management policies and robust PDMPs with mandatory access provisions suggests that 
these policies reduce the volume and dosages of opioids prescribed and dispensed. Specifically, drug 
supply management policies achieve their intended effect of reducing prescribing of higher-risk 
opioids (in terms of formulations, dosages, and quantity) while increasing access to less high-risk 
opioid prescriptions. Robust PDMPs with mandatory access provisions are associated with decreases 
in a variety of opioid prescribing measures, including total prescriptions, number of fills, and dosages. 
Research comparing robust PDMPs and mandatory access provisions to PDMPs without these 
provisions observed that the latter were not associated with similar reductions.
45
 Evidence on the 
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pharmaceutical, and public health approaches (eg, PDMPs and laws related to pain management 
clinics) effectively reduced opioids, especially among high-risk prescribers and users.  
Two rigorous evaluations suggest that naloxone access laws increase prescription naloxone 
dispensing.
84,85
 However, several low-rigor studies published after our article review suggest that 
many pharmacies fail to supply naloxone despite these laws. For example, researchers observed that 
only about a quarter of pharmacies dispensed naloxone two years after implementation of a 2016 
California naloxone standing order.
96
 An evaluation of a 2015 Texas naloxone access law with a 
standing-order provision observed that nearly 25% of audited pharmacies did not stock naloxone in 
2018.
97
 Future research should investigate barriers to pharmacist naloxone dispensing in states with 
standing-order provisions.  
 We found insufficient evidence regarding the effect of state interventions on patient health–
related outcomes across policies. Two or fewer studies evaluated patient health outcomes for all 
primary and secondary interventions, with the exception of PDMPs. Synthesis of the patient health 
effects of PDMPs is complicated by the use of varied outcomes, including overdose mortality; drug 
use, misuse, dependence, and initiation; health care use; and consideration of both illicit (eg, heroin 
and nonmedical prescription pain reliever use) and licit prescription drug use. Variation in outcomes 
poses similar challenges for evaluation of mandatory access provision effectiveness.       
Future research should concentrate on the effects of tertiary prevention policies on patient 
health outcomes. Studies assessing policies that influence access to opioid addiction treatment are of 
low rigor overall; however, initial evidence suggests that policies limiting access to methadone 
maintenance therapy may be associated with lower treatment use.
78,79,81,83
 Future investigations should 
rigorously evaluate variation in state funding for medications used in the treatment of opioid 
dependence, state-imposed Medicaid and private payor prohibitions on utilization management 
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requirements. Evidence from two rigorous evaluations suggests that Good Samaritan laws may 
increase hospitalizations, especially for heroin-related adverse health events, but do not influence 
opioid-related mortality.
29,76
 However, a controlled pre-post evaluation by McClellan and colleagues 
(2018), published after our article review, observed that Good Samaritan laws were associated with 
reductions in opioid overdose deaths.
98
 We captured only one study evaluating the effect of naloxone 
access laws on opioid overdose deaths, which demonstrated decreases in non-heroin opioid-related 
mortality but not heroin-related morality. The recent study by McClellan and colleagues also 
identified an association between naloxone access laws and reductions in opioid overdose deaths.
98
 
Unlike the prior study, McClellan and colleagues did not disaggregate opioid overdose deaths by 
opioid type.
98
 Future research should further explore the effects of Good Samaritan and naloxone 
access laws on patient health.  
Our review has two main limitations. First, we generally do not review evaluations of state 
programs not initiated by legislative or administrative actions. This limitation is particularly important 
when considering the small number of evaluations on naloxone access laws and anti-doctor-shopping 
policies. For example, previous research has identified a positive association between community-
implemented naloxone distribution programs and improved patient health outcomes, such as 
decreased overdose and increased recovery.
99,100
 Further, model-based studies provide additional 
evidence that increasing naloxone availability is associated with reductions in overdose 
mortality.
101,102
 Research on anti-doctor-shopping programs suggests that these programs reduce 
multiple prescriber and pharmacy use but may have an unintended consequence of increasing 
circumvented opioids.
103
 Although it is beyond the scope of this review to evaluate these programs, 
they add to the evidence base on what governments can do to address opioid misuse and overdose.  
Second, we limited our review to evaluations implemented by US states, thereby excluding 
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Specifically, a robust literature on syringe services programs, which provide sterile equipment to 
injection drug users, suggests that these policies reduce blood-borne infections.
104-106
  
 Beyond these limitations, our synthesis suggests a need for future research at the state policy 
level. First, research should examine policies included (eg, Good Samaritan and naloxone access 
laws) and absent (eg, opioid prescription limits and state policies affecting opioid dependence 
treatment among criminal justice populations) from our review that have received insufficient 
attention. Second, studies on opioid prescribing and dispensing policies should take a holistic 
perspective regarding policy effects by investigating (or highlighting as a potential limitation) 
unintended consequences, such as changes in illicit opioid use, underprescribing and clinically 
inappropriate opioid therapy tapers or discontinuation, and suicide; and differential effects of policies 
by socioeconomic status, race, ethnicity, and criminal justice involvement. And third, research should 
evaluate the effects of all policies on patient health outcomes, specifically overdose. 
Conclusions 
Our scoping review reveals a growing rigorous literature on the effects of state opioid misuse prevention policies on patient and 
provider outcomes, but persistent gaps in evidence remain. The evidence now more clearly suggests that drug supply management policies 
and robust PDMPs with mandatory access provisions reduce multiple opioid prescribing and dispensing measures. Despite the increase in 
rigorous evaluations, the literature on most state opioid misuse prevention policies remains limited, particularly as they relate to patient 
health outcomes. We recommend future research examine policies that have received insufficient attention, investigate unintended 
























Table 1. State Policies to Curb Opioid Misuse
a
 







Continuing medical education requirements on pain 
management or opioid prescribing. These requirements can 
be tied to licensure.  
Laws related to pain 
management clinic
b 
Policies that target inappropriate prescribing from health 







Recommendations to providers around opioid prescribing. 
Guidance documents vary but typically include opioid 
selection, dosage, duration, titration, and discontinuation; 








Laws and programs that restrict or prohibit patients from 
seeking or filling multiple opioid prescriptions from 







Policies that limit opioid prescribing by restricting quantity 
or dosage that can be prescribed and/or requiring payer prior 













An electronic database that collects, monitors, and analyzes 
controlled-substance prescribing and dispensing. Laws vary 
widely but can include which providers and state officials 
have access to the PDMP; mandatory prescriber and 
dispenser querying; interstate data sharing; update 
frequency; schedule of controlled substance monitored; and 
operating agency.  
Tertiary 
prevention 
Naloxone access laws Policies that increase lay access to naloxone. Laws vary but 
can include third-party prescriptions; pharmacist dispensing 
without a prescription; prescriber, dispenser, and layperson 
immunity from civil and criminal penalties; and standing-
order provisions. 
Good Samaritan laws Laws that offer legal protection to individuals who seek 
emergency help for a drug overdose.  
Policies affecting opioid 
addiction treatment 
Policies that influence access to treatments for opioid 
addiction, such as residential treatment and medication-
assisted therapy. Policies vary greatly but include mandating 
or restricting benefit coverage, modifying public funding for 
treatment, and imposing provider licensing requirements.  




This table includes interventions assessed in the research articles included in the scoping review. It is 
not exhaustive of all state strategies to address opioid misuse. As is identified in footnotes b and c, we 
acknowledge that some policies intend to influence multiple prevention categories. However, we use 








These interventions can also be considered secondary prevention. 
c 
These interventions could be considered primary, secondary, or tertiary intervention because they 
influence primary exposure to opioids, high-risk opioid exposure, and treatment access for individuals 
with an opioid dependence.  
Table 2. Study Characteristics 
Characteristic Number of Studies 
Total studies 71 
Publication year  
1980-2000 2  
2001-2005 0  






Interrupted time series with comparison 8  
Interrupted time series without comparison 8  
Controlled pre-post 28  
Uncontrolled pre-post 18  











Primary prevention 10 
Secondary prevention 42 
Tertiary prevention 12 




Anti-doctor-shopping laws 2 
Continuing medical education requirements 1 
Drug supply management  5 
Good Samaritan laws 2 
Naloxone access laws 3 
Opioid prescribing guidelines  5 
Laws related to pain management clinics 4 
Policies affecting opioid addiction treatment 7 
Prescription drug monitoring programs 38 
Combined effects of multiple policies 10 
a
 The totals from study design, intervention type, and intervention do not sum to 71 because certain 








Haffajee et al. (2018)
25
 is included in 2 study design categories: interrupted time series with 
comparison and controlled pre-post.  
c 
Kuo et al. (2016)
26
 and Meara et al. (2016)
27
 analyzed policies categorized in primary prevention and 
secondary prevention. Dowell et al. (2016)
28
 analyzed a primary prevention policy and the combined 
effects of multiple policies.  
d 
Kuo et al. (2016)
26
 and Meara et al. (2016)
27
 are in 3 intervention categories: anti-doctor-shopping 
laws, laws related to pain management clinics, and prescription drug monitoring programs. Dowell et 
al. (2016)
28
 is in 2 intervention categories: laws related to pain management clinics and combined 
effects of multiple policies. Rees et al. (2017)
29
 is in 2 intervention categories: naloxone access and 
Good Samaritan laws. 
Table 3. Primary Prevention 
Outcome Type 










Continuing medical education requirements  
Prescribing/dispensing  
*Very low due to 1 
evaluation and 




1 Decline in high-dosage opioids dispensed 
(Katzman et al., 2014)
30
  
Increase in low-dosage opioids dispensed 
(Katzman et al., 2014)
30
 
No change in opioid prescriptions filled 
(Katzman et al., 2014)
30
 
Laws related to pain management clinics 
Prescribing/dispensing 
c
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* Very low due to 






























































Effects concentrated among highest baseline 
opioid prescribers and highest baseline opioid 








No change in receipt of high-dosage or non-
long-term opioid receipt (Meara et al., 2016)
27
 
No change in prescription opioid dosage 
dispensed associated with pain clinic law alone 
(Dowell et al., 2016)
28
 




No change in schedule III opioids prescribed 




No change in 4 or more opioid prescribers 





No change in nonfatal prescription opioid 
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No change in prescription opioid overdose death 
rates associated with pain clinic laws alone 
(Dowell et al., 2016)
28
 












































Decline in total opioid prescriptions and total 
MME per month (Weiner et al., 2017)
32
 
Decline in total prescriptions greater than 3-day 
supply and total MME per month per 





Decline in opioids prescribed (Franklin, 2012)
33
 

























 See Appendix 4 for the modified GRADE Summary of Findings. The GRADE approach 
automatically rates observational studies a low quality of evidence score. Since all of our included 
articles use an observational approach, compared to a randomized trial, all policy/outcome pairs are 
initially given a low quality of evidence score. Policy/outcome groups can then be rated up or down. 
If the quality of evidence score is moved up or down from the low rating, we provide an explanation 
following the score. 
Table 4. Secondary Prevention
 
Outcome Type 












*Very low due to 






























No change in schedule II or III opioid 
prescriptions (Kuo et al., 2016)
26
 
No change in receipt of high-dosage 
opioids and non-long-term opioid 




No change in four or more opioid 
prescribers (Meara 




No change in nonfatal prescription 
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Drug supply management policies 
Prescribing/dispensing 
*Moderate due to 
magnitude and 





































































Decline in high-dose opioid 
prescriptions (Hartung et al, 2018; 
Keast et al., 2018)
37,38
 
Increase in low-dose opioids (Hartung 
et al, 2018; Keast et al., 2018)
37,38
 
No change in total opioids or opioid 
dosage between 61 and 120 MED 
(Hartung et al, 2018)
37
 
Stringent prior authorization policy 
associated with a reduction in 
controlled-release oxycodone use 
compared to lenient prior authorization 








Minimal decrease in total daily opioids 




Decline in multiple pharmacy visits 
(Hartung et al., 2018)
37
 
Decline in multiple prescriber use 
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*Very low due to 







No change in opioid-related emergency 
department visit or hospitalization 




Lower rates of opioid misuse in high 
and low prior authorization policies 
compared to no prior authorization 
policy (Cochran et al., 2017)
41
 
Lower rates of opioid overdose in low 
prior authorization policy compared to 
absence of prior authorization policy 
(Cochran et al., 2017)
41
 





































Decline in schedule II and III opioids 
prescribed (Moyo et al., 2017)
42
 
No change in total opioids and schedule 





Decline in schedule II opioids 
prescribed (Bao et al., 2016)
43
 and 






















































































(Reisman et al. 2009)
57
 
No change in high-dosage opioids 
prescribed (Buchmueller et al. 2018),
45
 
total opioids prescribed (Bao et al. 
2016; Buchmueller et al. 2018),
43,45
 
overall opioid dosage dispensed (Brady 
et al. 2014; Paulozzi et al. 2017),
44,46
 









No change in opioids prescribed 
(Baehren et al., 2010;
47
 Landau et al., 
2018
48
), controlled substances nor 





Higher odds of any analgesic 




Lower opioid and controlled-release 



























































































Decline in frequency of 2+ opioid 
prescribers and 4+ new patient visits 
(Ali et al., 2017;
52




No change in illegitimate opioid source 
(Ali et al., 2017)
52
 
No change in overlapping claims, 5+ 
prescribers, out-of-state prescribers and 




Decline in oxycodone-related mortality 
(Delcher et al., 2015)
53
 and overall 




No change in non-oxycodone- or 





Increase in prescription opioid and 



















Decline in past-year days used of 
NMPR
c
 and heroin (Ali et al., 2017)
52
 
Decline in inpatient drug rehabilitation 
admissions (Reisman et al. 2009)
57
 
No change in overall drug overdose 
mortality or opioid-related overdose 






No change in heroin or prescription 




No change in opioid-related poisonings 
(Buchmueller et al., 2018)
45
 
No change in prescription-drug- or 
heroin-related treatment admissions 
(Dave et al., 2017),
59
 emergency 
department visits involving an opioid 
(Maughan et al., 2015)
60
 
No change in past-year NMPR
c
 or past-
year heroin use, abuse/dependence, or 
initiation (Ali et al., 2017)
52
  
Smaller increase in intentional 














Abbreviations: ITS, interrupted time series; NMPR: Nonmedical prescription pain reliever.  
a
 See Appendix 4 for the modified GRADE Summary of Findings. The GRADE approach 
automatically rates observational studies a low quality of evidence score. Since all of our included 
articles use an observational approach, compared to a randomized trial, all policy/outcome pairs are 
initially given a low quality of evidence score. Policy/outcome groups can then be rated up or down. 
If the quality of evidence score is moved up or down from the low rating, we provide an explanation 
following the score. 
b 
We excluded the following studies from Table 4 because they evaluated PDMP provisions, not 
overall PDMPs, or compared robust to nonrobust PDMPs: Brown et al, 2017;
63
 Gilson et al., 2011;
64
 
Green et al., 2012;
65
 Haffajee et al., 2018;
25
 Kuo et al., 2016;
26
 Pardo et al., 2016;
66
 Phillips et al., 
2017;
67
 Rasubala et al., 2015;
68
 Ringwalt et al., 2015;
69
 Sigler et al., 1984;
70
 Suffoletto et al., 2018;
71
 
Sun et al., 2017;
72
 Wastila et al., 1996;
73
 Wen et al., 2017;
74
 and Yarbrough et al., 2018.
75
 See 
Appendix 2 for a detailed summary of these evaluations.  
c 
Low-dose opioids are prescriptions <61 morphine equivalent dose or short-acting opioids. High-dose 









Table 5. Tertiary Prevention
 
Outcome Type 















2 Increase in emergency department and 
inpatient hospital admissions for 




No change in opioid-related, non-
heroin-related, or heroin-related 
mortality (Rees et al., 2017)
29
 
No change in nonprescription use of 




Policies affecting opioid addiction treatment 
Patient health 




















Decline in high-dose buprenorphine 
fills following buprenorphine prior 




Increase in medium- and low-dose fills 
following buprenorphine prior 



























































Decrease in methadone maintenance 
enrollment after removal of methadone 




Patients who paid out of pocket for 
methadone treatment more likely to 
leave care than patients with benefit 




Increase in buprenorphine use 
associated with state funds to subsidize 
buprenorphine and state special 




No change in buprenorphine use 
associated with state regulating 
buprenorphine beyond federal standards 
(Andrews et al., 2014)
80
 
Greater use of opioid addiction 
treatment in states with Medicaid 
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Opioid addiction treatment use higher 
in states with Medicaid coverage than in 
states with block-grant coverage or no 
public coverage (Saloner et al., 2016)
83
  














































Increase in naloxone prescriptions 
associated with naloxone access law, 
lay dispensing, provider immunity 
(Gertner et al., 2018)
84
 
Increase in naloxone prescriptions 
associated with standing-order 




Increase in naloxone prescriptions 
associated with third-party provisions 
(Xu et al., 2018)
85
  
Decrease in naloxone prescriptions 
associated with third-party provisions 




Decrease in opioid-related and non-
heroin opioid-related mortality 











(Rees et al., 2017)
29
 
Decrease in opioid-related and non-
heroin opioid-related mortality 
associated with naloxone access laws 
that remove criminal liability for 
naloxone possession (Rees et al., 201)
29
 
No change in opioid-related mortality, 
non-heroin opioid-related mortality, and 
heroin-related mortality associated with 




No change in heroin-related mortality 
associated with naloxone access law, 
standing order, or removing criminal 





See Appendix 4 for the modified GRADE Summary of Findings. The GRADE approach 
automatically rates observational studies a low quality of evidence score. Since all of our included 
articles use an observational approach, compared to a randomized trial, all policy/outcome pairs are 
initially given a low quality of evidence score. Policy/outcome groups can then be rated up or down. 
If the quality of evidence score is moved up or down from the low rating, we provide an explanation 


















































































Decline in opioids prescribed by high-










Decline in percentage of high-risk 






Decline in opioid dosage dispensed 





Decline in opioid dosages prescribed by 










Decline in opioid dosage prescribed to 










No change in opioid dosages prescribed 






















































































No change in opioid dosage prescribed 







Decline in daily MEDs per patient for 
opioid, hydrocodone, oxycodone, 
methadone, and hydromorphone 
dispensed (Al Achkar et al., 2018)
89
  
Decline in opioids dispensed in the 
overall cohort, prior risk ,of opioid use 




No change in daily MEDs per patient 
for morphine, fentanyl, oxymorphone, 











Decline in diversion rates for 
oxycodone, methadone, and morphine 













No decline in diversion rates for 
fentanyl, hydromorphone, and 






Decline in oxycodone-related mortality 







Decline in prescription-opioid-related 








Smaller heroin-related mortality 
increase than comparison state 





Decline in overdose mortality due to 
oxycodone, methadone, hydrocodone, 






Increase in overdose mortality due to 
morphine, hydromorphone, and heroin 













 We do not provide a GRADE quality of evidence score for multiple policies because each article 
evaluates different components of the same group of policies or a different combination of policies 
entirely.  
b 
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Final number of results: 1546 
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Date Searched: 05/30/2018 
Final number of results: 1887 
 




Date Searched: 05/31/2018 
Final number of results: 381 
 




Date Searched: 06/05/2018 
Final number of results: 139 
 
Scopus Scoping Review Search Strategy (https://www-scopus-
com.proxy.lib.umich.edu/search/form.uri?display=basic) 
 
Date Searched: 06/05/2018 










Appendix 2: Articles included in scoping review 
Abbreviations 
(A)OR: (Adjusted) odds ratio 
ARCOS: Automated Reports and Consolidated Orders System 
CDC Wonder: CDC Wide-ranging Online Data for Epidemiological Research data 
CI: Confidence interval 
ED: Emergency department 
EM: Emergency medicine 
ER: Extended release  
FFS: Fee for service 
GSL: Good Samaritan Law 
HMO: Health maintenance organization 
IRR: Incident rate ratio 
LIP: Lock-in program 
LA(O): Long acting opioid  
MAT: Medication assisted treatment  
MCPP: Multiple Copy Prescription Program 
MED: Morphine equivalent dosage 
MME: Morphine milligram equivalent  
NAL: Naloxone Access Law 
NCHS: National Center for Health Statistics  
NDATSS: National Drug Abuse Treatment System Survey 
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NSDUH: National Survey on Drug Use and Health  
OAT: Opioid agonist therapy 
PA: Prior authorization 
PDMP: Prescription drug monitoring program 
PRRP: Patient review and restriction program  
RADARS: Researched, Abuse, Diversion, and Addiction-Related Surveillance System 
RR: Relative risk  
SA(O): Short-acting (opioid) 
SE: Standard error 
TEDS: The Treatment Episodes Data Set 
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day increased 
from 49.5% in 
2010 to 56.9% in 
2013.  



































by 80.1 (p < 0.01) 
MMEs prescribed 
per state residents 
per year and 
prescription opioid 
overdose deaths 
per 100,000 state 
residents by -1.198 
(p <0.01).  
 
Implementation of 
pain clinic laws 









combined nor pain 
clinic laws were 
associated with a 
statistically 
significant 
reduction in heroin 
Strengths: State 
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death rate.  






































with Parts A, B, 
and D coverage 
and not in an 
HMO and with 
no cancer 
diagnosis in the 
year before or 























Only state laws 
regulating pain 
clinics were 
associated with a 
significant 
reduction in 
schedule II opioid 
prescriptions (0.64 
95% CI: 0.47, 
0.89). No law was 
associated with a 
change in schedule 





































with decline in 
average MME per 
transaction (−0.57 
mg/month, 95% 
CI: -1.09, -0.06), 
opioid volume 
(kg) (-9.99, 95% 
CI: -12.9, -7.11), 
no. of opioid 
prescriptions 
(thousands) (-12.2, 
95% CI: -15.3, -
9.15), and quantity 
of opioid pills 
dispensed (-714, 
95% CI: -877, -
550).  
 

































patients with the 
highest baseline 


























2006-2012 Random 40% 
sample of all 
Medicare 
beneficiaries 
who were 21 – 
64 years of age 
and enrolled in 
fee for service 
Medicare Parts 




or end stage 

























































due to sample, 
aggregate 
policy measure  






























declined in 2008 
to 129.7 mg/day 
MED, in 2009 to 
113 mg/day MED, 






2007 to 2009 and 












2006-2010 Individuals ages 
18-64 enrolled 
in WA Medicaid 






























with a cancer 
diagnosis and 
dual eligible.   
prescription, any 
opioid poising, 







occurred at 10 




between 2006 and 
2010.  
 
Rates of other 
prescription opioid 
poisonings 
appeared to level 
off after 
implementation of 
the WA opioid 














2004-2010  Individuals 
enrolled in WA 
workers‘ 
compensation 
program aged 18 









Decline in mean 
monthly 
prevalence of 
opioid use by 
25.6% between 
2004 (14.4%) and 
2010 (10.7%). 
 
Decline in incident 
users who went on 
to chronic opioid 
therapy between 
pre-guideline 
period (6.3%, 95% 
CI: 6.1–6.6%) and 
post-guideline 
period (4.7%, 95% 
CI: 4.5–5.0%)   
 
Decline in high 
dose prescriptions 
















2006-2010 Individuals ages 
18-64 enrolled 
in WA Medicaid 
who had at least 



















unchanged at 37.6 
mg MED from 






the (-.44, 95% CI: 













dual eligible.   
(-1.82, 95% CI: -
2.14, -1.50); the 
95th (-4.29, 95% 
CI: -5.37, -3.22); 
and 99th 
percentiles (-






















Ohio PDMP Guidelines 
associated with a 
12.0% (95% CI: -
17.7, -6.3) 
reduction in the 
level of total 
opioid 
prescriptions per 
month and a 0.9% 
(95% CI: –1.1, –
0.7) decline in 





associated with a 
17.4% (95% CI: -
27.4, -7.3) 
reduction in the 
level of total 
MME per month 
and a –0.9% (95% 
CI: –1.3, –0.6) 





associated with an 
11.2% (95% CI: -
18.8, -3.6) 
reduction in the 
level of total 
monthly opioid 
prescriptions 
greater than a 3-
day supply and a 
0.9% (95% CI: –




associated with a 
24.8% (95% CI: -
43.5, -6.1) 
reduction in total 
MME per month 
for prescriptions 
greater than a 3-
day supply, and 
a –.9% (95% CI: –




surgery as a 





















(29.6%,  95% CI: 
–46.9%, –12.3%), 
oxycodone 
(20.8%, 95% CI: –
31.7%, –10.1%), 
codeine (16.3%, 
95% CI: –25.1%, 
–7.5%),  and 
hydrocodone 
(11.3%, 95% CI: –
15.6%,  –6.9%), as 
well as small 
declines in trend. 
 
Guidelines were 












Anti-doctor shopping laws  





























with Parts A, B, 
and D coverage 
and not in an 
HMO and with 
no cancer 
diagnosis in the 
year before or 























Only state laws 
regulating pain 
clinics were 
associated with a 
significant 
reduction in 
schedule II opioid 
prescriptions (0.64 
95% CI: 0.47, 
0.89). No law was 
associated with a 
change in schedule 

















































2006-2012 Random 40% 
sample of all 
Medicare 
beneficiaries 
who were 21 – 
64 years of age 
and enrolled in 
fee for service 
Medicare Parts 




or end stage 

























































due to sample, 
aggregate 
policy measure  










PA for 1 
opioid), and 
no PA (i.e., no 
















treatment, not in 
long term care 
for 90 or more 






Lower rates of 
opioid abuse 
among High PA 
(ARR: 0.89 (95% 
CI: 0.85-0.93) and 
Low PA (ARR: 
0.93, 95% CI: 
087-1.00), 































above 120 mg 
per day 
2011-2013 Individuals 
enrolled in either 











period and were 





ve claims  
Policy 
implementation 
associated with a 
reduction in the 
estimated monthly 
probability of an 
opioid prescription 
> 120 mg per day 
MED by 1.7% 





associated with an 
increase in 
estimated monthly 
probability of an 
opioid prescription 
< 61 mg per day 
MED by 1.0% 




associated with a 
decrease in 
multiple pharmacy 












120 MED.   
 








































2007-2009 Oklahoma (OK) 
and Oregon 
(OR) Medicaid 
fee for service 
beneficiaries 
aged 18 – 64 
that were not 
dual eligible and 
were enrolled 
for a minimum 
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therapy acting opioid 
count (0.3633), 









ER/LA opioid as a 


















use (-0.0050), and 
multiple prescriber 
use (-0.0704). No 
significant change 
in high dosage 
opioid use or 
opioid-related 
hospitalization or 










(2) strict or 
lenient policy 
1996-2005 Outpatient FFS 
Medicaid 
prescription 
claims in 49 










PA resulted in a 
non-significant 
0.19 reduction in 
controlled-release 
oxycodone use 







from -0.76 to 0.09.  
 
A strict PA policy 
associated with a 
0.34 reduction in 
controlled-release 
oxycodone use 
(95% CI: 0.47, 
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associated with a 
0.06 reduction 








2014 Patients aged 18 
years or older 
who 
purchased at 
least 1 SAO 









period and were 
continuously 


















from 6.8 mg pre to 




in: mean total 






and proportion of 
patients 
purchasing >120 





exceeded the SAO 
limit at baseline: 
















in mean total daily 
dose of long acting 




long acting opioid, 
and proportion of 
patients 
purchasing >120 








Prescription drug monitoring programs 
























12 years or older 
in the United 
States 












associated with an 
approximately ten-
day reduction in 
days of NMPR use 




associated with an 
approximately 20-
day reduction in 

















year days of 






associated with a 
56% reduction in 
the odds of having 
two or more 
prescribers as a 
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80 
associated with an 
80% reduction in 
the odds of having 
two or more 
prescribers as a 
source for non-
medical opioid 
prescriptions (p < 
0.05). PDMPs 
without access or 
enrollment 
provision 
associated with a 
56% change in 
having two or 
more prescribers 















social sources and 
illegitimate 











patients age 18 





head, joint, or 













altered for 41% of 
patients 
 
In cases of altered 
prescribing, 61% 
resulted in fewer 





resulted in patients 
prescribed more 
painkillers than 






one third of 
patients in data 








for patient or 
provider 
characteristics 
Bao 2016 PDMP  2001-2010 Patients age 18 
or older who 
reported pain as 
a reason for a 
visit to an office-










associated with a 
3.7-5.5% 
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Schedule II opioid 







opioid of any kind 
and pain 
medication overall  
 
Reduction in 
schedule II opioids 
was significant in 


































each state  
Controlled 
pre-post 
ARCOS Binary PDMP 
associated with a 
reduction in 
MMEs per capita 
(-0.033, p = 0.69). 
The impact of 




per capita was 
434.39 (SE: 22.99) 





678.27 (SE: 17.51) 
governed by board 
of pharmacies, and 
478.01 (SE: 29.56) 
governed by other.  





per capita was 
551.02 (SE: 25.66) 

























494.27 (SE: 14.80) 







per capita was 
531.25 (SE: 23.80) 
in states with laws 
that impose no 
expectation on 
practitioners and 












































Less than daily 
data collection 





compared to daily 


































Change in the sign 
of the slope for the 
distribution of 
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in New York 









-3.31, p < 0.001) 
and after (b = 
2.73, p < 0.001) I-
STOP. 
 
Increase in the rate 
of heroin overdose 
morbidity from 
before (b = 30, p < 
0.001) to after (b = 
101.9, p < 0.001) 
I-STOP 
 
Increase in the rate 




(b = 38.3, p = 
0.001) and after (b 











in the rate of 
overdose 
morbidity due to 
prescription 
opioids before and 





































associated with a 
statistically 
significant 
increase in filling 
at 5 or more 
pharmacies 
(0.001) and in 
proportion of 
patients with 4 or 
more new patient 





taking opioids, for 
211+ days supply, 
120+ daily MED, 
overlapping 
claims, 5+ 




























out of state 
pharmacies, and 









0.007, 95% CI: -
0.0133, -0.0004), 
overlapping claims 
(-0.006, 95% CI: -
0.0095, -0.0016), 
5+ prescribers (-
0.002, 95% C: -
0.0035, -0.001), 
5+ pharmacies (-
0.001, 95% CI: -
0.0015, -0.003), 
and 4+ new patient 







associated with a 
change in 211+ 
days supply, 120+ 
daily MED, out of 
state prescribers, 







associated with the 
greatest 
reductions.   
Curtis 
2006 









year 2000, and 
filled at least one 
prescription drug 










PDMP had 36.5 
fewer opioid 
analgesic claims 
per 1,000 total 
prescription claims 
compared to 
counties without a 
PDMP (p < 0.01). 
Counties with 
PDMP had 2.0 
fewer controlled-
release oxycodone 

























without a PDMP 
(p < 0.01).  
relevant 
policies 



























associated with 5.8 






18-24, 3.2 (p < 
0.1) admissions 
among individuals 
aged 25-44, and 
0.35 (p < 0.01) 
fewer admission 
among individuals 
aged 45+. Effect 
not statistically 
significant for 
ages 12-17.  
 














































registered for the 















from 16.9 to 15.0 
per capita per 
quarter during the 







decrease in total 
number of daily 
MME dispensed 
































more (6.04) opioid 
patients with an 
average daily 
MME >/= 90 than 
nonregistered 






















































security form was 
associated with a 
sustained 
prescribing 
increase for SA 
hydromorphone 
(5.215, p < .001), 
meperidine 
(10.256, p < .001), 
and SA oxycodone 
(5.504, p < .001). 
No prescribing 
changes were 


































can not be 
directly access 







PDMP at the 


























7.8 % of Rhode 
Island pharmacist 
had used the 
PDMP compared 
to 67.9 % of 
Connecticut 
pharmacist (p < 
0.01) 
Limitations: 
Small sample (n 
= 210), 
response bias, 


















e, timely data 



























aged 18-64 with 
opioid fills at 
any time during 













difference in mean 
opioid fills per 
enrollee:  -16.15 in 
Kentucky vs. 
Mississippi (p < 
0.001), -6.79 in 
New Mexico vs. 
Texas (p < 0.001), 
-5.23  in 
Tennessee vs. 
Georgia (p < 
0.001), and -2.93 
in New York vs. 




difference in mean 
MED dispensed 
per enrollee 
equaled -18.33 in 
Kentucky vs. 
Mississippi (p < 
0.001), -10.72 in 
New Mexico vs. 
Texas (p < 0.01), -
10.43 in 
Tennessee vs. 





























0.01), and -10.54 
in New York vs. 









20.42 in Kentucky 
vs. Mississippi (p 






difference in mean 
quarters with 
opioid Rx filled 
by ≥3 doctors per 
enrollee: -40.44 in 
Kentucky vs. 







difference in mean 
quarters with 
opioid Rx filled by 
≥3 pharmacies per 
enrollee: -38.06 in 
Kentucky vs. 



























with Parts A, B, 
and D coverage 
and not in an 
HMO and with 
no cancer 
diagnosis in the 
year before or 





















Only state laws 
regulating pain 
clinics were 
associated with a 
significant 
reduction in 
schedule II opioid 
prescriptions (0.64 
95% CI: 0.47, 
0.89). No law was 
associated with a 



























































that they planned 
on prescribing an 
opioid analgesic in 





resulted in no 





























1999-2008 All drug 
overdose deaths 

















PDMP states (aRR 
1.11; 95% CI: 










PDMP state (aRR 
1.14, 95% CI: 
















































PDMP state (aRR: 
1.13, 95% CI: 




















PDMP state (aRR: 
1.17, 95% CI: 
1.02, 1.34). No 
statistically 
significant 













PDMP state (aRR: 
1.13, 95% CI: 















variation in drug 
overdose mortality  





































































PDMP was not 
associated with a 
difference in the 
































2013, 2014 Patients aged 18 
or older treated 
in the immediate 




excluded if they 
were not directly 
discharged from 




data was not 







There was no 
change in the 






























2006-2012 Random 40 % 










































who were 21 – 
64 years of age 
and enrolled in 
fee for service 
Medicare Parts 




or end stage 
renal disease or 
receiving 
hospice care 

















































































was not associated 
with a change in: 
total opioid 
volume of 
Schedule IV or V 
opioids; mean 





























declined by 3.73 
mg/ prescription 











There were no 
changes in older 
adults and PDMP 
beneficiaries. 



























with reductions in 
mortality due to 
overall drug 
overdose or to 




synthetic opioids.  
 
PDMPs in 
operation ≥ than 5 
years associated 
with higher rates 
of overall drug 
overdose mortality 
using both the 
underlying cause 
of death data 
(1.39, p = 0.02) 
and multiple cause 
of death data 
(1.36, p = 0.01). 
PDMPs in 




rates due to legal 




(0.94, p = 0.04), 
illicit drugs (0.82, 








that is male, 
white, high 
school educated 
or better (age 
25 or older), 
uninsured, 
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94 
other drugs (1.16, 
p = 0.02).  Not 
statistically 


















death in all 50 





PDMP states did 




overdose rate than 
no PDMP states (p 
= 0.18)  
 
Every 1-point 
increase in PDMP 
strength was 
associated with a 
0.01 (significant at 
p = 0.01) 
reduction in 
overdose deaths 
related to opioid 
pain relievers in 
model 1. Every 1-
point increase in 
PDMP strength 
was associated 
with a 0.015 
(significant at p = 
0.05) reduction in 
overdose deaths 
related to opioid 
pain relievers in 
model 2. 
 
PMPs in the third 
quartile were 
associated with an 
approximately 
0.18 (95% CI: -
0.34, -0.016) 
reduction in opioid 
overdose death 
rates compared 
with states without 
a PMP. PMPs in 
the 1st, 2nd, and 4th 
quartiles did not 
have a statistically 
significant 
different effect 
than no PMP.  
 
Effects of NAL, 
GSL, and pain 




for GSL, pain 
clinic 
management 


























































death rates (AOR: 
-1.12, p < 0.001).   
 
Four or more drug 
schedules 
monitored 
associated with a 
decrease in opioid-
related overdose 
death rates (AOR: 
-0.55, p < 0.05) 
 
Data updated at 
least weekly 
associated with a 
decrease in opioid-
related overdose 
death rates (AOR: 
-0.82, p < 0.001) 
 






























































PDMP states and 
proactive states 
did not have a 
statistically 
significant 
difference, in drug 
overdose deaths, 
opioid-related 
mortality rate, nor 
mean MME rates 
than non PDMP 
states and non-






























the PDMP (II 
only or II-III, 
II-IV, II-V), 
































































than states without 
PDMPs 
(aRR=1.008, 95% 
CI: 1.005, 1.01).  
 







that there was no 
change in 
poisoning in states 




poisoning rates in 
states without such 
features. This 
included PDMPs 
requiring daily or 




query the PDMP 
data in certain 
situations, those 
with schedule II-
IV or schedule II-
























2011-2014 Residents of 50 







associated with an 




rate per 100,000 









increased by 0.056 
compared with 
states without 


























2013 Every patient 




























who received pain 
medications, there 







post-2 (9.6%) (p < 
0.05). The odds of 
a patient needing 
opioid analgesic 
decreased over 






(452) and post-1 
(190) and post-2 
(140) I-STOP (p 
<0.0001). No 
change in non-











PDMP 2003-2009 74 opioid 
treatment centers 
from 33 states 
Controlled 
pre-post  





quarter by 1.019 
without PDMP 
(95% CI: 1.008, 
1.030) and 1.002 
with PDMP (95% 






quarter by 1.049 
without PDMP 
(95% CI: 1.036, 
1.063) and 1.026 





























reduction in the 
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facilities in 14 
states with 







370.9, p = 0.019).  
 





























PDMP and (2) 
the mean 
number of 
























substance fills   
Limitations: 
Large 6-month 
















1981-1982 All prescriptions 
for schedule II 
drugs dispensed 
to ambulatory 









prescriptions as a 
percentage of total 
prescriptions from 
1.57 in 1981, 0.55 
in 1982, and 0.57 
in 1983 
 
60.4% decrease in 
schedule II drugs 









































PDMP, PDMP had 




99% CI: 1.19, 
1.20; aOR 
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(aOR e+pPDMP =  
0.54, 99%CI: 0.53, 
0.55), followed by 
ePDMP states 
(aOR ePDMP = 
0.76, 99%CI: 0.75, 
0.77) relative to 
non-PDMP states.  
 
The odds of 
receiving schedule 





















2015-2017 All patients aged 




month from 15 
emergency 
departments in 












Decline in opioid 
prescribing rate by 
-12.4 % (95% CI: 
10.8, 14.1) over 


































or nursing care, 
and enrolled for 















reduction in the 
proportion of 
visits with opioid 
prescribing (5.8/1,
000 encounters, 
95% CI: –0.11, 
11.8) or total 
dispensed MME 
(2.66, 95% CI: -
0.15, 5.48).  
 











and query rate 

























MCPP 1989 38,384 patient 







MCPPs had a 
negative influence 
(-1.11, p ≤ 0.001) 
on schedule II 
opioid use and a 
positive influence 
(0.59 p ≤ 0.001) 
on schedule III 
opioid use. There 




and schedule IV 




















2011-2014 Number of 
prescription fills 








of Schedule II 
opioid 
prescriptions per 
quarter was 15.3 
in states without 
any mandate and 
13.9 in state with a 





associated with a -
1.49 reduction in 




compared to no 
registration 




associated with a -
1.90 reduction in 




compared to no 
registration 
mandate (p <0.05) 
 
Access mandate 
associated with a 
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18 access to 
patient 
information 






























physician for:  
- Opioids 
overall: 2%, p 
< 0.01 
- Oxycodone: 
5.2%, p < 
0.01 
- Hydrocodone: 




with a 1.4% 
increase in days 
supply prescribed 
per physician of 
schedule IV 
opioids (p< 0.05).  
 
PDMPs were not 
associated with 
changes in days 











schedule II, or 











data on dose 
strength  
Tertiary prevention 





2010-2012 270 hospitals in 










 Good Samaritan 
laws associated 






to opioids (IRR: 
1.21, 95% CI: 
1.00, 1.48) and 
heroin (IRR: 1.34, 
95% CI: 1.00, 




(IRR: 0.98, 95% 






























with a 0.043 
reduction in all 
opioid-related 




and no change in 
heroin related 
mortality (all 
values were not 
statistically 







associated with a 
0.015 reduction in 
all opioid-related 








values were not 
statistically 








0.134 decrease in 
the number of 
opioid-related 
deaths (p < 0.01), 
a 0.134 decrease 
in the number of 
deaths involving 
opioids other than 
heroin (p < 0.05), 
and a 0.169 
decrease in heroin-
related deaths (not 
statistically 
significant at p = 
0.05) 
 
Adoption of Good 
Samaritan laws 
was associated 
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with a 0.101 






and a 0.070 
increase in heroin-
related mortality 
(all values were 
not statistically 
significant at p = 
0.05).   
 
Neither naloxone 
access laws nor 
Good Samaritan 
laws were 
associated with a 
change in non-
prescription use of 
prescription 
painkillers.  
Opioid addiction treatment policies 
Andrews 
2014 


























2011: OTPs that 
participated in 

















States that regulate 
buprenorphine 
beyond federal 
standards had 1.23 
higher odds of any 
use of 
buprenorphine, 
0.69 lower odds of 
use for 
detoxification, and 
1.06 higher odds 
for maintenance. 
None of these 
values were 
statistically 
significant at p < 
0.05.  
 




2.06 higher odds 
of any use of 
buprenorphine, 
2.51 higher odds 
for detoxification, 
and 1.81 higher 
odds for 
maintenance. All 
of these values 
were statistically 
significant at the p 
























1.94 higher odds 
for any use of 
buprenorphine, 
4.55 higher odds 
for detoxification, 
and 2.88 higher 
odds for 
maintenance. Only 













2013, 2014 Pregnant women 
age 18-44 who 
reported using 








insurance   
Cross-
sectional 





more likely to 
receive OAT in all 
settings (32.9%, 






15.5, -64.8), and 
non-intensive 
outpatient (37.9%, 










































with a diagnosis 
of opioid 
dependence who 












The percentage of 
members filling 
doses greater than 
24 mg/day 
decreased from 




dose group.  
 
Increase from 
34.1% - 37.5% in 
medium dose (> 
16 and ≤ 24 mg) 
and from 44.3% - 
54.3% low dose (≤ 
16 mg) groups 

























but returned to 
pre-policy trends 
by the end of 2008 













2002, 2003 Single childless 
adults aged 18 to 
64 addicted to 
opiates eligible 
for the Oregon 
Health Plan  
Uncontroll















had 60% lower 
odds of being 




to the prior year (p 


































ed pre-post  
Primary data 
collection 
Of the 68 
individuals who 
self-paid, 23 left 
treatment. 
 
Of the 48 
individuals who 
did not lose the 




























































72.7% of the no 
naltrexone group 
experienced a 
relapse and 9.1% 
of the naltrexone 
group experienced 






























TEDS  45.0% of 
Medicaid-enrolled 
individuals used 




30.1% in states 
with block grant 
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coverage 17.0% in states 
with no coverage 
(p = < 0.01). 
account for if 
difference were 





















order, & (5) 
lay dispensing 






Medicaid in all 








provision in place 
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of opioids 
dispensed in both 
the recipient (-
72.7, p ≤ 0.01) and 
provider (-67.2, ≤ 




with a trend 
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effect model but 
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associated with 
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6.19, p ≤ 0.01), 
and 
hydromorphone (-
3.54, p ≤ 0.05). No 
statistically 
significant effect 






The effect of the 
policy was greater 
for males (-3.68, 
p ≤ 0.01) than 
females (-2.80, p ≤ 
0.01) and greater 
for 0-20 years (-
27.26, p ≤ 0.01) 
than 20-40 years (-
3.00, p ≤ 0.01), 
40-60 years (-2.45, 
p ≤ 0.01), 60+ 
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each within the 
first and last 3 
months of study 
period, and filled 
prescriptions 
from stress 
reporting data to 
QuintilesIMS 
within the first 





>3 prescribers and 
>3 pharmacies to 
acquire opioids 
during any 90-day 
period) 
experienced a 
reduction in MME 
per transaction (-
1.08 p < 0.01), 
total opioid 
volume (-0.55 p < 
0.01), days 
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by 80.1 (p < 0.01) 
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per year and 
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residents by -1.198 
(p <0.01).  
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(95% CI: -0.79, -
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1.79 (95% CI: -
2.55, -0.93) from 
January-December 
2011, and -3.02 
(95% CI: -4.31, -
1.57) from 
January-December 
2012) lower than 
what would have 
been expected had 
the changes in 
mortality rate 
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been the same as 
changes in trends 
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1.7%) in opioid 
dispensed within 3 
days of visit in 
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policy 
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were observed for 
oxycodone (-1.31, 
p < 0.05), 
methadone (-0.23, 
p < 0.01), 


























controlled trial  
Experiments in which units are assigned exposure to a 





Study observes outcomes at multiple time points pre- and 
post- a specific legal intervention. Stronger designs 




Study evaluates an outcome for a population on either side 




Study observes outcomes before and after a legal 




Study observes outcomes before and after a legal 
intervention but without a comparison not exposed to the 




Study observes outcomes after a legal intervention but 
without a comparison not exposed to the legal 










Study measures outcome variable at one point in time 
after the intervention. Stronger designs adjust for potential 
confounding. 
a 
This classification system intends to provide a simplified hierarchy of design types to assist 
policymakers in assessing public health law research.   It is neither exhaustive of all study designs nor 
does it incorporate study quality variation within the same research design. For instance, it is possible 
that a well-designed and analyzed quasi-experimental or observational studies may be more 
appropriate for causal inference than a poorly conducted randomized controlled trial. For readers 
interested in limitations of specific studies, see Appendix 5.  
Appendix 4: GRADE Summary of Findings
a,b 






























Prescribing/dispensing ITS without 
comparison 
1 Very low 
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in results  
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access laws  
Prescribing/dispensing Controlled 
pre-post 
2 Low Some 
inconsistency in 















 One evaluation 
a
 GRADE grades of evidence: high quality – further research is very unlikely to change our 
confidence in the estimate of effects; moderate quality – further research is likely to have an important 
impact on our confidence in the estimate of effect and may change the estimate; low quality - further 
research is very likely to have an important impact on our confidence in the estimate of effect and is 
likely to change the estimate; very low quality – we are very uncertain about the estimate.  
b
 The GRADE approach automatically rates observational studies a low quality of evidence score. 
Since all of our included articles use an observational approach, compared to a randomized trial, all 
policy/outcome pairs are initially given a low quality of evidence score. Policy/outcome groups can be 
rated up or down. If the quality of evidence score is moved up or down from the law rating, we 
provide an explanation following the score. 
c 
Policy/outcome pair with only one study. We acknowledge that the GRADE framework rates the 
quality of evidence for each outcome, not each study. Thus, the quality of evidence score for 
policy/outcome pairs with only one evaluation are inherently limited due to the sole evaluation. 
Consequently, we rated all policy/outcome pairs with one evaluation a very low GRADE quality of 
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